Quarterly ResultMay 11, 2026, 04:10 PM
Perspective Therapeutics Q1 Net Loss $26.2M; Cash $271M, Clinical Progress
AI Summary
Perspective Therapeutics, Inc. reported a business update and Q1 2026 financial results, showing a net loss of $26.2 million. The company significantly strengthened its financial position with cash, cash equivalents, and short-term investments totaling $271 million as of March 31, 2026, following a $164 million underwritten offering in February. This provides a cash runway into late 2027 to support planned clinical milestones and operational investments. The company also highlighted continued progress across its three clinical-stage oncology programs and expansion of its manufacturing infrastructure, with multiple clinical catalysts anticipated in 2026.
Key Highlights
- Cash, cash equivalents, and short-term investments were $271M as of March 31, 2026.
- Cash runway is expected into late 2027, supported by a $164M offering in February 2026.
- Q1 2026 R&D expenses increased 50% to $21.4M from $14.3M in Q1 2025.
- Q1 2026 G&A expenses decreased 10% to $7.0M from $7.8M in Q1 2025.
- Net loss for Q1 2026 was $26.2M ($0.25/share) compared to $18.2M ($0.25/share) in Q1 2025.
- Chicago manufacturing site construction is on track to complete in 2026.
- Multiple clinical catalysts are expected in 2026 across VMT-α-NET, VMT01, and PSV359 programs.